昌吉怀孕做无痛人流最佳时间昌吉有没有正规男科医院,昌吉哪家医院做人流好而且便宜,昌吉妇科疾病到哪里治疗,昌吉韩式包皮手术的费用是多少,昌吉做次包皮手术多少钱,昌吉正规人流手术费用,昌吉市博爱医院做无痛上环怎么样

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

DUBLIN, June 27 (Xinhua) -- The Irish government is aiming to increase internet literacy among older people with the launch of a 1.6 million euro training program, according to a cabinet minister on Monday.The goal of the scheme is to provide basic internet skills to 30,000 elderly people across the country who are less likely engage with the internet themselves.The announcement was made by Irish communications minister Pat Rabbitte at a new computer training facility run by Age Action Ireland, an Irish charity which promotes positive aging and better policies and services for older people.The Irish minister detailed how the training program will help those involved."This scheme will enable thousands of people throughout Ireland, people otherwise likely to be left behind in the knowledge society, to acquire the basic practical know-how to improve their digital skills. In particular this will help older people, those with disabilities, the unemployed and other key target groups. They will learn to use the internet, emails and how to conduct simple on-line transactions," he said."Previous schemes show that learning such basic skills helps people in many ways, giving them new communication options, new opportunities to save money, as well as better access to a wide range of on-line services," he added."We have also seen how such new skills and the opportunities that result from them improve people's confidence and wellbeing. More widespread participation in the knowledge society is a win- win outcome with advantages for citizens, government and the wider economy."

WASHINGTON, Aug. 4 (Xinhua) -- U.S. scientists have found two gene mutations occurring in oligodendrogliomas, the second-most common form of brain cancer, according to a study to be published Friday in journal Science.For years scientists have been looking for the primary cancer genes involved in oligodendrogliomas evolvement. Scientists know the two chromosomes held the probable mutations, but the particular gene information remains unclear.Now scientists at Duke University Medical Center and Johns Hopkins University have discovered the most likely genetic mutations that researchers have been hunting for on chromosomes 1 and 19.The genes they identified, CIC or FUBP1, are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments, said Hai Yan, a Duke associate professor of pathology and co-corresponding author of the study.The researchers found CIC on chromosome 19 and FUBP1 on chromosome 1 based on an initial study of seven oligodendrogliomas. They found six mutations and two mutations, respectively, in the seven tumors. Further study of 27 more of these tumors showed that there were 12 and three mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes.These genes were difficult to find until the technology improved, said Yan."The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced," Yan said. "A mutation frequency of 85 percent is very high."The finding of two additional new genes involved in oligodendrogliomas increases the chances for an effective combination drug therapy for the tumor, Yan said. He envisions a combination cocktail of drugs similar to the combination-drug treatments taken by HIV patients that would target different pathways involved in cancer, and assist both in reducing the chance of relapsing and increasing odds of success.

BEIJING, Aug. 11 (Xinhuanet) -- Next year will bring a doubling in the size of the words that appear on cigarette packages to warn consumers of the dangers of smoking. Starting in April 2012, cigarettes produced and sold in China will bear a new warning label containing letters that will be no less than 4 millimeters in height. That will be twice the size of the current minimum, which stipulates that the letters be at least 2 mm from bottom to top, according to a notice written by the China National Tobacco Corp and published on the State Tobacco Monopoly Administration's website. Despite the intentions, many tobacco-control experts said the step is "minor" and that it fails to deal with the chief issue. "There is no use in making the font size even 100 times bigger if the warning is pointless," said Wu Yiqun, deputy director of the ThinkTank Research Center for Health Development, a Beijing-based non-governmental organization that advocates for the adoption of stronger smoking-control measures. Both Wu and Yang Gonghuan, director of the tobacco control office of the Chinese Center for Disease Control and Prevention, said the warning that now appears on cigarette packs is too weak. It says: "Smoking is harmful to your health. Quitting early is good for your health." "The package should inform consumers of the dangers of smoking in accordance with requirements adopted by the World Health Organization Framework Convention on Tobacco Control. (It should say that) smoking causes lung cancer, coronary disease and makes people grow old," Yang said. China decided in 2005 to ratify the convention, which also requires that tobacco warnings cover a third of the surface of cigarette packs. "Even if the size of the words is doubled, it still doesn't meet those standards," Yang said. "The Chinese practice is to draw a line to demarcate a third of a cigarette package, where the warning should be, but the words put on it are still very small." Experts said graphic health warnings could be printed on cigarette packs and used as a "scientific, direct and shocking" deterrent to smoking.Throughout the world, more than 1 billion people in 19 countries live under laws that require the packaging of various types of tobacco products to bear large, graphic health warnings. They often show pictures of black lungs and festering mouth sores, according to the World Health Organization. China, though, is excluded from those rules. Both Wu and Yang said the fundamental barrier to better control of tobacco use in the country is the fact that the China National Tobacco Corp, the country's largest cigarette-maker, is a subsidiary of the State Tobacco Monopoly Administration, China's tobacco regulatory body.

COPENHAGEN, May 30 (Xinhua) -- The number of confirmed E. coli cases has risen to 14 in Denmark, with at least 26 others suspected of having the intestinal infection, the National Serum Institute said Monday.Seven of the confirmed cases show symptoms of kidney failure which marks an advanced stage of the sickness, the institute said."Almost all of the 14 infected people have been in northern Germany recently except just one. There is a 24-year-old man from Jutland. He has not even been to Germany, so he does not quite fit with the rest of the pattern," said Kaare Moelbak, chief physician at the institute. "We do not know yet how he has been so unlucky to get this infection but we assume that it has been a person-to-person transmission, or that he has eaten infected vegetables," he added.Denmark's Veterinary and Food Administration (DVFA) had advised Danish consumers not to eat raw tomato, lettuce and cucumber from Germany, and cucumber from Spain.It is now checking Danish cucumbers for traces of E. coli, with results expected on Tuesday.